Stirling goes back to the drawing board

By Melissa Trudinger
Monday, 07 March, 2005

Stirling Products (ASX:STI) will extend its proof-of-concept studies to include a more direct delivery method after analysis of levels of its beta agonist ST810, a single enantiomer form of salbutamol, in the bloodstream of merino lambs showed that the growth promoter was not getting into the bloodstream.

Significantly, the positive control, a mixed enantiomer form of salbutamol, also failed to get into the bloodstream.

Managing director Calvin London said that as a result, sufficient plasma levels of the drug were not achieved, and no significant physical effects such as reduction in fat or increase in muscle were observed.

Now, the company plans to look at using a more precise controlled release delivery directly into the tissue. The follow-on study is expected to begin in April.

Related News

Nature helps to relieve physical pain

Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd